Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.07

Autolus Therapeutics plc (NASDAQ:AUTL) gapped up before the market opened on Friday . The stock had previously closed at $4.07, but opened at $4.50. Autolus Therapeutics shares last traded at $4.61, with a volume of 782,622 shares trading hands.

Analyst Upgrades and Downgrades

Several analysts recently commented on AUTL shares. Truist Financial lifted their price objective on Autolus Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, April 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Autolus Therapeutics in a report on Friday, April 12th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.70.

Autolus Therapeutics Stock Up 10.8 %

The company has a fifty day simple moving average of $5.04 and a 200-day simple moving average of $5.31. The firm has a market cap of $1.20 billion, a P/E ratio of -3.87 and a beta of 2.03.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.18). As a group, research analysts forecast that Autolus Therapeutics plc will post -0.71 EPS for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Several large investors have recently made changes to their positions in the business. EWA LLC increased its stake in Autolus Therapeutics by 40.2% during the fourth quarter. EWA LLC now owns 25,678 shares of the company’s stock worth $155,000 after acquiring an additional 7,361 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Autolus Therapeutics by 66.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 27,034 shares of the company’s stock worth $172,000 after buying an additional 10,771 shares during the period. EntryPoint Capital LLC lifted its holdings in shares of Autolus Therapeutics by 113.6% during the 1st quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock valued at $137,000 after purchasing an additional 11,456 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in shares of Autolus Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 48,849 shares of the company’s stock valued at $315,000 after purchasing an additional 12,387 shares during the last quarter. Finally, Privium Fund Management B.V. lifted its holdings in shares of Autolus Therapeutics by 43.2% during the 1st quarter. Privium Fund Management B.V. now owns 50,058 shares of the company’s stock valued at $319,000 after purchasing an additional 15,091 shares during the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.